TMCnet News
Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor ConferencesCAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences. Events: Morgan Stanley Virtual Annual Global Healthcare Conference H.C. Wainwright 23rd Annual Global Investment Conference A webcast of both presentations can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com About Foghorn Therapeutics Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology. Media Contact: Fanny Cavalié, Foghorn Therapeutics Inc. Gregory Kelley, Ogilvy Investor Relations Contact: Ben Strain, Foghorn Therapeutics Inc. Hans Vitzthum, LifeSci Advisors |